Cargando…
Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes
Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE...
Autores principales: | Del Barba, Paolo, Del Tedesco, Federica, Frontino, Giulio, Guarneri, Maria Pia, Bonfanti, Riccardo, Barera, Graziano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039355/ https://www.ncbi.nlm.nih.gov/pubmed/35493474 http://dx.doi.org/10.3389/fimmu.2022.853561 |
Ejemplares similares
-
Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021) -
Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn’s Disease
por: Barni, Simona, et al.
Publicado: (2021) -
Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
por: Comberiati, Pasquale, et al.
Publicado: (2019) -
Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023) -
OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)